Axogen Inc Stock Price, News & Analysis

Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, announced plans to release its first quarter 2023 financial results on May 9, 2023, before market opening. Management will conduct a conference call at 8:00 a.m. ET to discuss the results, which investors can join via phone or online. Axogen specializes in technologies for nerve regeneration and repair, with a portfolio that includes products like Avance^® Nerve Graft and Axoguard Nerve Connector^®. These products are designed to restore nerve function and improve patient quality of life. Axogen's innovations are available in multiple countries, demonstrating its international reach and commitment to patient care.

Axogen reported Q4 2022 revenue of $36.2 million, marking a 17% increase compared to Q4 2021. The company logged a net loss of $5.4 million or $0.13 per share, consistent with the previous year. Adjusted net loss improved to $1.1 million from $3.3 million. The full-year revenue reached $138.6 million, up 12% from 2021. The company anticipates 2023 revenue between $154 million and $159 million. Axogen faced challenges with cash management due to $8 million held at Silicon Valley Bank, which became accessible after the FDIC intervention on March 13, 2023.

Axogen, Inc. (NASDAQ: AXGN) announced the appointment of Marc Began as Executive Vice President and General Counsel, effective March 20, 2023, replacing Brad Ottinger. Began brings over 20 years of legal experience from companies like Abiomed and Novo Nordisk. He will oversee legal and compliance activities under the leadership of Karen Zaderej, Chairman and CEO. Additionally, the company reported inducement grants under NASDAQ listing rules, awarding stock options and restricted stock units to both Began and Chief Marketing Officer Jens Schroeder Kemp. These grants include stock options for 90,000 shares for Began, with an exercise price of $8.16.

Axogen (AXGN) has announced it will release its fourth quarter 2022 financial results on March 14, 2023, before market opening. The company specializes in surgical solutions for peripheral nerve injuries and will host a conference call and webcast at 8:00 a.m. ET on the same day. Investors can participate via phone or listen online through the Axogen website. The company emphasizes its commitment to offering innovative, clinically proven solutions to aid in peripheral nerve repair, with a diverse product portfolio available in multiple countries.

Axogen, Inc. (NASDAQ: AXGN) announced the appointment of Jens Schroeder Kemp as Chief Marketing Officer on February 13, 2023. With over 20 years of experience in medical technology, Kemp will lead the company's marketing strategies and report to Karen Zaderej, Chairman and CEO. His previous role was Vice President of Marketing at Ambu Inc., where he significantly contributed to the single-use endoscopy market. The company aims to leverage Kemp's experience to enhance surgeon adoption and drive innovation in its nerve repair solutions, which include products like Avance Nerve Graft and Axoguard.